文献速递认知障碍与痴呆神经肌肉病

C9orf72重复扩增家系中疾病早现的临床证据

Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion.
PubMed 文献 · JAMA Neurol · 2017-01-01

这项比利时家系队列研究纳入36个C9orf72重复扩增家系,分析244人的发病年龄、病程和死亡年龄。结果显示 successive generations 发病年龄逐代提前(P < .001),而病程和死亡年龄无代际效应,支持C9orf72家系存在疾病早现。

要点

  • C9orf72重复扩增家系中发病年龄逐代提前,支持疾病早现。
  • 病程长短和死亡年龄未观察到代际效应。
  • 该发现有助于确定症状前携带者开始临床随访的年龄。

核心结论

  • C9orf72重复扩增家系存在疾病早现,表现为发病年龄逐代提前。

研究设计与样本

  • 2000年6月16日至2016年6月1日在36个比利时C9orf72重复扩增家系中开展的队列研究,共244人(132例证实或肯定携带者),其中147例临床受累(89例证实或肯定携带者)。

主要发现

  • 111例有发病年龄资料者(66男45女,平均[SD]年龄57.2[9.1]岁)中,从最早出生代到最晚出生代的平均[SD]发病年龄分别为62.5[8.3]、57.1[8.2]、54.6[10.2]和49.3[7.5]岁。
  • 对所有受累和未受累高危亲属的删失回归分析证实 successive generations 发病年龄下降(P < .001)。
  • 病程或死亡年龄未观察到代际效应。

临床怎么用

  • 临床可考虑对C9orf72重复扩增携带者根据家系发病年龄提前趋势,更早开始临床随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients carrying a C9orf72 repeat expansion leading to frontotemporal dementia and/or amyotrophic lateral sclerosis have highly variable ages at onset of disease, suggesting the presence of modifying factors. OBJECTIVE: To provide clinical-based evidence for disease anticipation in families carrying a C9orf72 repeat expansion by analyzing age at onset, disease duration, and age at death in successive generations. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was performed from June 16, 2000, to June 1, 2016, in 36 extended Belgian families in which a C9orf72 repeat expansion was segregating. The generational effect on age at onset, disease duration, and age at death was estimated using a mixed effects Cox proportional hazards regression model, including random-effects terms for within-family correlation and kinship. Time until disease onset or last examination, time from disease onset until death or last examination, or age at death was collected for for 244 individuals (132 proven or obligate C9orf72 carriers), of whom 147 were clinically affected (89 proven or obligate C9orf72 carriers). MAIN OUTCOMES AND MEASURES: Generational effect on age at onset, disease duration, and age at death. RESULTS: Among the 111 individuals with age at onset available (66 men and 45 women; mean [SD] age, 57.2 [9.1] years), the mean (SD) age at onset per generation (from earliest-born to latest-born generation) was 62.5 (8.3), 57.1 (8.2), 54.6 (10.2), and 49.3 (7.5) years. Censored regression analysis on all affected and unaffected at-risk relatives confirmed a decrease in age at onset in successive generations (P < .001). No generational effect was observed for disease duration or age at death. CONCLUSIONS AND RELEVANCE: The clinical data provide supportive evidence for the occurrence of disease anticipation in families carrying a C9orf72 repeat expansion by means of a decrease in age at onset across successive generations. This finding may help clinicians decide from which age onward it may be relevant to clinically follow presymptomatic individuals who carry a C9orf72 repeat expansion.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Van Mossevelde S, van der Zee J, Gijselinck I, et al. Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. JAMA Neurol. 2017. PMID: 28192553. doi:10.1001/jamaneurol.2016.4847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。